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ABSTRACT 
Background 
Achieving hepatitis C elimination is hampered by the costs of direct acting antiviral treatment and 
the need to treat hard-to-reach populations. Treatment access could be widened by shortening or 
simplifying treatment, but limited research means it is unclear which treatments or strategies could 
achieve sufficiently high cure rates to be acceptable, particularly in settings with a high prevalence of 
less common viral genotypes. We present the statistical aspects of a multi-arm trial designed to test 
multiple strategies simultaneously with a monitoring mechanism to detect and stop those with 
unacceptably low cure rates quickly.  
Methods 
The VIETNARMS trial will factorially randomise patients to two drug regimens, three treatment 
shortening strategies or control, and adjunctive ribavirin or no adjunctive ribavirin with shortening 
strategies (14 randomised groups). We will use Bayesian monitoring at interim analyses to detect 
and stop recruitment into unsuccessful strategies, defined as a >0.95 posterior probability of the 
true cure rate being <90%. Final comparisons will be non-inferiority for regimen and strategy 
comparisons and superiority for the ribavirin comparison. Here, we tested the operating 
characteristics of the stopping guideline, planned the timing of the interim analyses and explored 
power at the final analysis.  
Results  
A beta(4.5, 0.5) prior for the true cure rate produces <0.05 probability of incorrectly stopping a 
group with true cure rate >90%. Groups with very low cure rates (<60%) are very likely (>0.9 
probability) to stop after ~25% patients are recruited. Groups with moderately low cure rates (80%) 
are likely to stop (0.7 probability) before the end of recruitment. Interim analyses 7, 10, 13 and 18 
months after recruitment commences provide good probabilities of stopping inferior groups. For an 
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overall true cure rate of 95%, power is >90% to detect non-inferiority in the regimen and strategy 
comparisons using 5% and 10% margins respectively, regardless of the control cure rate, and to 
detect a 5% absolute difference in the ribavirin comparison. 
Conclusions 
The operating characteristics of the stopping guideline are appropriate and interim analyses can be 
timed to detect failing groups at various stages. Our design is therefore suitable for selecting 
treatment shortening or simplifying strategies. 
Trial Registration 
ISRCTN registry: ISRCTN61522291. Registered on 4th October 2019. 
KEYWORDS 
Bayesian methods, Clinical trial, Hepatitis C, Interim analyses, Multi-arm, Trial design 
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BACKGROUND 
Oral direct acting antivirals (DAAs) have transformed the treatment of hepatitis C (HCV). Compared 
to historical injectable interferon-based treatment of 6-12 months, they are more effective, better 
tolerated and offer shorter durations of therapy (8-12 weeks). However, access to treatment is still 
limited by costs, particularly in low-income countries where the patient pays at least in part. Further, 
achieving the WHO target for elimination of viral hepatitis as a public health threat by 2030 (1) will 
require curing hard-to-reach populations including the homeless, drug users and prisoners who still 
find adherence challenging. Strategies designed to reduce drug exposure while still achieving HCV 
cure, could further widen treatment access, but there has been limited research to date into 
shortening and simplifying HCV treatment with DAAs. 
Previous very small studies assessing shortened DAA treatment have found higher cure rates when 
treatment length is guided by early response to treatment (2-4), or when adding adjunctive 
therapies, such as pegylated interferon (PEG-IFN) (5), to DAAs. Outside of HCV treatment, drug 
sparing strategies that allow intermittent dosing are widely used in the treatment of tuberculosis, 
allowing patients who may not comply with daily treatment to access supervised treatment. 
Although these approaches may also be successful in HCV, there are currently no studies assessing 
such a strategy with DAAs. There has also been little research into the use of DAAs in genotype 6, a 
strain that is most prevalent in Vietnam and surrounding countries (~50%), but uncommon 
elsewhere (<5%) (6). Several small studies have shown very high cure rates with DAAs in this 
genotype (7-10), as in other genotypes, but these have been mostly limited in regimen and to 
standard length courses. Finally, three pan-genotypic regimens (sofosbuvir/velpatasvir, 
sofosbuvir/daclatasvir, pibrentasvir/glecaprevir) are recommended by the most recent WHO 
guidelines (11), but there has been no direct randomised comparison of these regimens to date in 
any genotype. 
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As there is very little data to inform optimal ways to shorten HCV treatment, especially in genotype 
6, it is possible that any proposed shortening strategy may fail. Therefore trial designs that include 
multiple different options whilst allowing for the early stopping of unsuccessful treatments in order 
to focus on more successful treatments are essential, both for trial efficiency and to protect patients. 
Two trial designs that incorporate both of these aspects are factorial trials and multi-arm multi-stage 
(MAMS) trials. Both designs allow for greater efficiency in trials by reducing the number of patients 
required and shortening the time needed to test multiple interventions compared to sequential 
trials of individual interventions (12, 13). However, as the timing and maximum number of interim 
analyses within MAMS trials have to be pre-specified (14) they may not be suitable for interventions 
where the effect on outcomes is unknown and additional analyses may have to be scheduled.  
Data monitoring and stopping guidelines are most commonly framed within a frequentist framework 
with guidelines based on p-values or conditional power. When planning interim analyses care must 
be taken to control type I error, which can limit the ability to change the monitoring schedule to 
adapt to accumulating data, which may lead to delays in stopping unsuccessful treatments (if strict 
guidelines such as Haybittle-Peto (p<0.001) are used) or treatments being prematurely stopped. 
Monitoring can be improved by using a Bayesian approach, which allows for stopping guidelines that 
are based on directly interpretable probabilities and, as the prior is continuously updated, greater 
flexibility in the timing and numbers of interim analyses (15-18). Incorporating Bayesian monitoring 
within a multi-arm factorial trial allows for a flexible monitoring schedule to test multiple strategies 
and detect inferior ones quickly. 
Here, we present the statistical aspects of the design of a multi-arm trial to be conducted in Vietnam 
that aims to find efficacious drug-sparing treatment strategies that will allow access to HCV 
treatment to be widened, with a particular focus on increasing evidence on treatment of genotype 6. 
METHODS 
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Trial design  
VIETNARMS is a parallel-group open-label factorial trial (ISRCTN61522291). 1092 patients will be 
factorially randomised: 1:1 to two different WHO recommended dual DAA regimens 
(sofosbuvir/velpatasvir vs sofosbuvir/daclatasvir); 1:2:2:2 to standard licenced 12-week treatment vs 
4 weeks treatment with PEG-IFN+DAA vs 4-12 weeks response guided therapy (RGT) vs 12 weeks 
treatment using an induction/maintenance approach; and, if not randomised to standard 12-week 
treatment, 1:1 to adjunctive ribavirin vs no ribavirin for the duration of their DAA treatment (Figure 
1). Randomisation will be stratified by genotype 6 vs all other genotypes. Patients randomised to the 
PEG-IFN strategy will receive DAAs for 4 weeks with weekly PEG-IFN for 4 weeks starting at day 7. 
Treatment length for those randomised to RGT will be determined by HCV viral load (VL) at day 7 
and based on predicted viral kinetics (19): those with VL <lower limit of quantification (LLOQ) will 
receive 4 weeks of treatment, those with VL LLOQ-250 IU/ml will receive 8 weeks and all others will 
receive 12 weeks. Patients randomised to induction/maintenance will receive 12 weeks of 
treatment: 2 weeks of daily treatment (induction phase) followed by 10 weeks of 5 days treatment 
per week taking weekends off from the first weekend following their full 2 weeks treatment. Each 
strategy reduces DAA exposure and has other benefits, for example, compatibility with directly 
observed therapy programmes (as used for tuberculosis), but with other additional costs (Table 1). 
Within the trial, any patient not achieving cure with their first-line treatment will receive 12 weeks 
retreatment with the alternate drug regimen to the one they were originally randomised plus 
ribavirin. 
Primary endpoint 
The primary endpoint is Sustained Virologic Response (SVR12) i.e. virological cure on first-line 
therapy defined as plasma HCV VL <LLOQ 12 weeks after the end of first-line treatment (EOT+12) 
without prior failure. Failure is defined as either two consecutive HCV VL >LLOQ after two 
consecutive HCV VL <LLOQ with the latter confirmatory VL >2000 IU/ml, or two consecutive HCV VL 
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>1log10 increase above HCV nadir on treatment and >2000 IU/ml (either definition being met whilst 
on treatment or after finishing treatment during follow-up). 
These failure criteria identify patients who, were they not to receive retreatment before EOT+12 
weeks, would definitively have HCV VL >LLOQ at 12 weeks post-EOT and hence would be considered 
as failures in the primary endpoint. However, for ethical reasons, within the trial such patients will 
be offered retreatment as soon as they are definitively identified as having failed first-line 
treatment. Failure is defined using a higher threshold than the LLOQ because patients have been 
observed to achieve cure despite having low-level viraemia at EOT or shortly after, and so they do 
not need retreatment to achieve cure on first-line treatment. In practice, any participant with low-
level viraemia <2000 IU/ml either cures or viral load rises above this level. This will be carefully 
reviewed by the independent Data Monitoring Committee (DMC). This is the same definition as used 
in the UK STOP-HCV-1 trial (ISRCTN37915093) and SEARCH-1 trial in Vietnam (ISRCTN17100273), 
where the DMC has similarly reviewed individual patient viral load trajectories. 
Monitoring 
For the strategies to be viable outside the trial, first-line cure rates need to be high (>90%). The 
design of the trial therefore allows for failing groups to be stopped early at any time and subsequent 
patients to be randomised to more successful groups. Individual performance of groups receiving 
shortening strategies will be monitored during recruitment by an independent DMC who will make 
decisions on whether a group should be stopped. Groups receiving standard 12-week treatment will 
not be monitored as this is the licenced duration with cure rates >90% (20, 21). Interim analyses will 
not be comparative as the aim of monitoring is not to find the best strategy, but to find any strategy 
that meets a minimum acceptable cure rate that may also be non-inferior to standard treatment as 
different strategies may benefit different patient populations. 
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Analyses of cure rates will follow the Bayesian paradigm to allow the probability of the true cure rate 
being below different thresholds to be calculated: recruitment into a group will stop if there is a 
>0.95 posterior probability of the true cure rate being <90% (Pr(true cure rate <0.9|x)>0.95 where x 
is the data currently observed). The primary monitoring is combined across genotypes; if the 
combined group reaches the stopping guideline, each genotype stratum will be tested separately 
and the DMC will have the discretion to stop only those strata reaching the stopping criteria. 
Differences in stopping groups across strata is only likely to occur when there are extreme 
differences in the cure rates between the strata, which is not expected, and so the operating 
characteristics of the trial are based on stopping combined strata only. If neither stratum reaches 
the stopping criteria despite the combined strata doing so, it will be at the discretion of the DMC 
whether to stop recruitment into  
At interim analyses, there is greater uncertainty about the performance of the shortening strategies. 
Therefore, when determining the prior it was assumed that one strategy would fail completely such 
that all 4 groups receiving that strategy, of a total of 12 tested, would meet the stopping guideline. 
The mean of the prior was fixed at 0.9 and the effective sample size of the prior was varied until a 
distribution was found such that there was a ~0.33 probability of a cure rate <90%. The prior chosen 
was beta(4.5, 0.5) with mean 0.9, variance 0.015 and a 0.34 probability of a cure rate <90%. The 
relatively low precision of the prior will allow greater influence of the data in the posterior 
distribution. If the stopping guideline is met, sensitivity analyses using priors informed by observed 
cure rates in other randomised groups or strata will be performed and will be provided to the DMC 
to help inform their decision to stop a group. 
Sample size 
For the monitoring of single groups, assuming a target cure rate of 90%, an unacceptably true low 
cure rate of 70%, 90% power and one-sided alpha=0.05, and 5% loss to follow up by EOT+12, 39 
patients would be required per group to exclude the null hypothesis that the cure rate was 90% 
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based on a single-group test. There are 14 groups and 2 genotype strata, giving a total sample size of 
1092 patients (39*14*2). For final comparisons at trial closure, the null hypothesis is that all groups 
will achieve the >90% cure target and be included in the final analysis. There will then be 546 per 
group for the regimen comparison, 156 in the control group and 312 per intervention group for the 
strategy comparison, and 468 per group for the ribavirin comparison. 
Regulatory guidance recommends that non-inferiority margins be chosen to ensure that the 
difference between an intervention and the active control (here 12 weeks duration) would not 
exceed that between the active control group and a hypothetical placebo (or other standard control 
group, here the previous standard of care of 12-48 weeks PEG-IFN) (22). As cure rates with 12-48 
weeks PEG-IFN were ~70% in genotype 6 (23), with similar or lower cure rates in other genotypes, 
and as we expect >90% SVR12 in all groups, both our non-inferiority margins of 5% for the regimen 
comparison and 10% for the strategy comparison would ensure this.  
The choice of the non-inferiority margin was based on clinical judgement and the size of margins 
used in other trials of anti-infectives with relatively low failure rates such as community-acquired 
pneumonia (22). In particular, a smaller 5% margin is chosen for the drug comparisons because in 
practice they are likely to have similar advantages and disadvantages. In contrast, the different drug-
sparing strategies have a variety of different advantages and disadvantages (in terms of additional 
visits vs. less drug vs. different drugs vs. weekends off, Table 1) which could be differentially 
balanced against overall cure rates, particularly considering impact on healthcare provision, e.g. 
through directly supervised therapy. Thus a greater non-inferiority margin is relevant to drug-
shortening because the potential benefit in terms of numbers treated for the same fixed budget is 
much greater.  
From initial power calculations, assuming that the overall cure rate is 95%, the numbers above 
provide 97% power to demonstrate non-inferiority between drug regimens based on a 5% margin 
and 96% power to demonstrate non-inferiority between shortening strategies based on a 10% 
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margin, both with one-sided alpha=0.05. For superiority comparisons (conducted for ribavirin and 
any comparison that meets non-inferiority above) and two-sided alpha=0.05, these numbers provide 
>90% power to detect absolute differences in SVR12 of 5% for regimen or ribavirin comparisons and 
>80% power to detect absolute differences in SVR12 of 7% or more for the strategy comparisons. 
Statistical analysis 
The final analysis will estimate risk differences between groups using marginal effects after logistic 
regression. The model will include all main randomised effects and strata, and will test interactions 
between all randomisations. Interactions will only be included in the final model if the 95% credible 
interval for the interaction term excludes no effect (p<0.05 for frequentist analyses). The interaction 
between regimen and strategy will include all levels of strategy. The interaction between ribavirin 
and strategy will not include the standard treatment length strategy due to the partial factorial 
randomisation. Comparisons of regimens and of strategies will be non-inferiority analyses and the 
ribavirin comparison will be a superiority analysis. Primary analysis will be intention-to-treat using 
Bayesian methods and 90% credible intervals. Secondary analyses will consider per-protocol 
populations, frequentist methods, and 95% credible and confidence intervals.  
Analysis priors for the final analysis are listed in Table 2; these differ from the monitoring priors as 
the aim of monitoring is only to identify poorly performing groups and not to compare the 
randomised groups. The control cure rate analysis prior is beta(4.75, 0.25), which has a mean of 0.95 
and a variance derived as for the monitoring priors. Sensitivity analyses will use a range of 
informative priors reflecting plausible belief in the clinical community. Sceptical analysis prior 
distributions were chosen with means corresponding to the null hypothesis for each randomisation 
and enthusiastic analysis priors with means y greater than this, where y is the non-inferiority margin 
or absolute difference specified in the power calculations. The variances were arbitrarily set such 
that 90% of the prior distribution is within +/- y around the mean to reflect the strength of the belief 
in the mean effect. Thus for example, the risk difference for the drug regimen comparison has the 
11 
 
sceptical analysis prior centred on -5% (the null hypothesis for the non-inferiority comparison) with 
90% limits ±5%, giving a 0.05 probability that the cure rate will be 10% worse and a 0.05 probability 
the cure rate will increase (ie be >0%) (sceptical priors in each direction will be used for the regimen 
comparisons). The enthusiastic analysis prior is centred on 0% with 90% limits ±5%, giving a 0.05 
probability that the cure rate will be 5% worse and a 0.05 probability that it will be 5% better with 
one regimen than the other. 
To define the performance characteristics of the proposed stopping guideline, posterior probabilities 
of cure rates and the probability of stopping groups were calculated analytically using beta and 
binomial distributions respectively. Timings of interim analyses were determined by applying the 
probabilities of stopping groups to a projected recruitment schedule. The average probability of 
stopping a genuinely inferior group was estimated by integrating the probability of stopping a group 
with respect to the monitoring prior beta(4.5, 0.5) over cure rates between 60% and 90%. The lower 
bound was determined from previous studies testing strategies most similar to those in VIETNARMS 
which have reported cure rates of >90% with lower confidence interval bounds >60% (4, 5). In 
studies with cure rates <60%, all patients received shortened therapies, regardless of their HCV VL, 
and did not receive adjunctive drugs (24, 25), therefore they were not considered relevant to this 
analysis – although power would be even greater to stop such a group. Cure rates above 90% were 
not considered as groups with these cure rates should not be stopped and so do not affect timing of 
the analyses. Simulations of 5000 datasets with outcomes taken from binomial distributions were 
used to determine the cumulative probability of stopping groups at specified analysis time points, 
and to estimate power after being analysed using marginal effects after logistic regressions with a 
model containing all randomised comparisons, as described above. Predictive probabilities (the 
probability of achieving a success at the end of the trial) were calculated analytically using the beta-
binomial distribution in R 3.5.1. All other analyses were performed using Stata v15.1. 
RESULTS AND DISCUSSION 
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Characteristics of Bayesian stopping guideline for individual groups 
The minimum number of failures required to satisfy the stopping criteria for the main monitoring 
beta(4.5, 0.5) prior and for each number of analysed patients are listed in Table 3. The probability of 
stopping a group is then the probability of observing the required number of failures in the group. 
When the true cure rate is 90%, the probability of incorrectly stopping a group is always <0.05, and 
this decreases as the true cure rate increases. It is expected from the specification of the stopping 
guideline that when the true cure rate is equal to the mean of the prior, then the probability of 
stopping a group is 0.05 so the probability of incorrectly stopping a group is always maintained 
below the correct level. The calculated probability is not exactly 0.05 and differs depending on the 
number of patients analysed due to the discrete nature of the outcome. 
For small numbers of analysed patients, a larger proportion of failures are required to stop a group, 
increasing from a minimum of 17% to 100% of those analysed; therefore the probability of stopping 
a group incorrectly early in recruitment is also smaller as there is a smaller chance of observing 
greater proportions of failures regardless of the true cure rate. This protects against groups being 
stopped erroneously due to a high concentration of failures amongst the initial patients reaching 
EOT+12, and if the two strata within a group share the same true cure rate then it is unlikely only 
one will reach the stopping threshold. 
Groups with the lowest cure rates considered plausible (60%) are highly likely to reach the stopping 
criteria quickly (>90% chance of stopping after analysing 21-26 patients). Groups with moderately 
low cure rates (<80%) are also likely to be stopped before recruitment ends. However, groups with 
true cure rates slightly under 90% are unlikely to be stopped (results not shown). A low chance of 
stopping a group just below the target cure rate might be considered unacceptable in futility 
stopping guidelines in other situations, but the target of 90% is largely arbitrary and there may be 
interest in strategies that have a slightly lower cure rate if they are able to expand treatment access 
to difficult to reach populations. Increasing the probability of stopping groups with cure rates just 
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below 90% would lead to a greater chance of incorrectly stopping groups with cure rates >90% and it 
is considered more important to retain these than to stop groups with slightly lower cure rates. 
Additionally, any other stopping guideline would similarly be unable to discriminate between these 
cure rates without a very large sample size. The probability of incorrectly not stopping a group 
rapidly decreases as the true cure rate decreases. 
Timing of interim analyses 
Interim analyses need sufficient numbers of patients at EOT+12 to give a reasonable probability of 
stopping a genuinely inferior group. It was therefore decided to perform analyses after the first 
month such that at least one inferior group has a 0.3, 0.5 or 0.7 average probability of being stopped 
were this to be the first interim analysis, assuming cure rates are uniformly distributed on [0.6, 0.9] 
and given projected recruitment. An average probability is used to reflect the uncertainty about the 
true cure rates; for low cure rates the probability of stopping a group can be substantially higher 
(Figure 2). An additional analysis before these thresholds will allow for any groups with a very low 
cure rate below the anticipated minimum of 60% to be detected early despite the very small 
probability of detecting a group with a cure rate between 60-90%. 
Four analysis timepoints were chosen to provide multiple opportunities to detect failing groups 
while allowing adequate time between analyses for the accrual of patients and outcome data, and 
preventing unnecessary burden on time and resources needed for analyses and subsequent DMC 
meetings. The highest probability threshold (0.7) is determined by the maximum average cure rate 
of the genuinely inferior groups and by the recruitment schedule, as analyses need to be performed 
sufficiently early enough to gain the benefit of randomising remaining patients to the other groups. 
The other thresholds (0.3, 0.5) were evenly spaced across the probabilities of stopping a group with 
an average cure rate, taking into consideration the first, early DMC meeting not based on these 
probabilities. 
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Based on the underlying projected recruitment, we therefore expect the interim analyses to take 
place after 7, 10, 13 and 18 months. The number of patients in each group and the probability of 
stopping an inferior group of each strategy type at these analyses are listed in Table 4. By assessing 
the cumulative probability of stopping a group (Supplementary Figure 1, Additional File 1), our 
schedule provides a balance between having more frequent meetings, which have a lower 
probability of stopping groups at any individual meeting but allow for earlier detection of poorly 
performing groups, and less frequent meetings, which have a higher probability of stopping a group 
but its low performance is detected later. The exception to this is having analyses every month, but 
this schedule is impractical due to the resources required for an interim analysis. 
As this is only projected recruitment, sensitivity analyses were performed to examine the effect of 
faster or slower recruitment (Supplementary Table 1, Additional File 1). These indicate that changes 
to the recruitment schedule alter only the timing of the analyses; the number of patients in each 
analysis differs by less than the estimated number recruited in 1 month. Therefore, if there are 
significant delays in recruitment, interim analyses will be timed such that they include a similar 
number of patients at EOT+12 to that in the expected schedule. Sensitivity analyses also explored 
changing the lower bound of the distribution over which cure rates of genuinely inferior groups are 
assumed to be distributed to below 60% (Supplementary Table 2, Additional File 1), but this had 
minimal effect on the timing of initial interim analyses. There were greater differences in the timings 
of the last analyses, but the timing of this analysis is the most flexible and can be determined based 
on observed rather than assumed true cure rates.  
Power for final analysis 
Given the lack of knowledge of the standard 12-week cure rates for this population (anticipated 50% 
of patients with genotype 6) and how cure rates in the shortened treatment with ribavirin groups 
will compare to these and to shortened treatment without ribavirin, there is uncertainty regarding 
the overall power for the final analysis even if the overall cure rate is 95% (Table 5). If we assume 
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equality between regimens and a 5% absolute difference for ribavirin, then these constraints mean 
that the cure rates in each group are completely determined by the difference between the 
shortening strategies. Non-inferiority can exist between the standard duration group and either the 
pooled shortening strategy groups, the shortening strategy without ribavirin groups, or the 
shortening strategy with ribavirin groups, meaning the shortening strategy with ribavirin groups can 
have cure rates 2.5% higher, 5% higher or equal to the standard duration groups respectively. These 
alternatives are shown in different columns of Table 5. 
Power to determine non-inferiority for the regimen comparison using a 5% margin is mostly 
unaffected by assumptions about different values for the standard 12-week cure rate and effect of 
ribavirin, with power remaining close to 100%. Power to determine non-inferiority in the strategy 
comparison using a 10% margin is similarly unaffected, with power remaining close to 100% when 
comparing the pooled shortening strategy groups against standard duration. For superiority 
comparisons, power to detect a 5% absolute difference in the ribavirin or regimen comparison 
remains high at >90% regardless of the standard duration cure rate and ribavirin effect.  
Limitations of the design 
A potential weakness in the design is that the sample size was not originally calculated using 
Bayesian principles, but primary analyses will be conducted using Bayesian methods to allow for the 
calculation of posterior probabilities exploring the difference in cure rates between the 
interventions. However, for the non-inferiority comparisons, sample size estimates obtained using 
Bayesian methods are similar to or smaller than those obtained using frequentist methods (26), 
suggesting that our design is likely to be conservative. Additionally, secondary analyses will use 
frequentist methods for comparison. For interim analyses, the probability of correctly stopping a 
group, analogous to the frequentist concept of power, is determined by the true cure rate in the 
group and the number of analysed patients at each analysis, not by the overall group size.  
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The timing of and the number of patients at interim analyses are determined by at least one group, 
usually the 4 week treatment group with PEG-IFN since this has the shortest overall treatment 
duration, reaching a certain probability threshold of being stopped. This may mean delays in 
identifying unsuccessful groups receiving other strategies. This is unlikely if groups have cure rates 
lower than the average cure rate because, as discussed above, these will be detected faster than 
anticipated, but delays may occur if the cure rate is above the average, but <90%. As the treatment 
length of patients in the RGT groups is unknown until after their day 7 visit, it is not possible to 
stagger treatment start dates so that the length between randomisation and EOT is the same for all 
strategies. Staggered treatment start might also lead to drop out after randomisation but before 
starting treatment, leading to inefficiency and potential bias. Cure rates will be monitored and if the 
timing rule is found to be inappropriate it can be adjusted to change the timing or frequency of 
analyses with no penalty, due to the use of Bayesian monitoring (16).  
The power calculations for the final analysis assume that all groups will be included and that no 
groups have been stopped. It is possible that power will be lower if fewer groups are included, but 
for most comparisons with a full sample, power is very high and is likely to remain acceptable at the 
final analysis even with the exclusion of some patients. To help preserve power, if groups are 
stopped early subsequent patients will be randomised to open groups. The power calculations were 
also estimated using frequentist methods, though the primary analysis will use Bayesian methods. 
However as power is extremely high, the analogous concept to power in Bayesian analysis, that for 
non-inferiority comparisons the lower credible interval bound is above the non-inferiority margin, is 
likely to be similarly high. 
Alternative designs 
Alternative Bayesian designs include basing the stopping guideline on a predictive probability, the 
probability of achieving a success at the end of the trial. In VIETNARMS, a success during the 
monitoring period is stopping a genuinely inferior group, which means that there is a >0.95 posterior 
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probability of a <90% true cure rate in that group. A rule based on predictive probabilities would 
then state a group will be stopped at an interim analysis if there is a >0.95 chance of stopping a 
group at the end of the trial (Pr([Pr(true cure rate<0.9|z)>0.95]|x)>0.95 where x is the data currently 
observed and z the complete data with all outcomes observed). For the monitoring beta(4.5, 0.5) 
prior and a fully recruited group, the stopping criteria is met with 13 failures so equivalently the 
group is stopped if there is a >0.95 chance of observing ≥13 failures in the fully recruited group. 
Predictive probabilities place a large emphasis on the arbitrary target cure rate of 90%, and hence 
was not used for VIETNARMS. The final analysis will compare strategies against control and not test 
cure rates in individual groups. The aim of monitoring is to detect poorly performing groups and stop 
them early, rather than to ultimately meet a particular cure rate within a group at the end of the 
trial, as there may be other advantages to strategies that have a slightly lower cure rate than 90% in 
specific populations or circumstances. Compared to the posterior probability based stopping 
guideline, using predictive probabilities requires a similar number of failures or more to stop a group 
(Supplementary Table 3, Additional File 1) so they do not offer any benefits in detecting poorly 
performing groups more quickly for our design. Stopping rules and guidelines based on posterior 
probabilities can be converted to those based on predictive probabilities (27) so interim analyses can 
incorporate predictive probabilities to provide more information to the DMC.  
Another approach would be to analyse the outcome data after every reported outcome rather than 
at scheduled interim analyses, which could reduce the time until a genuinely inferior group is 
stopped. Implementing this would be complex due to the many groups and varying treatment 
lengths. The small benefit in the reduction in time would not justify the additional work required to 
monitor outcomes intensely.  
CONCLUSIONS 
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We have designed a trial allowing for the testing of multiple approaches to drug choice and 
shortening strategy for HCV treatment. We have closely examined the statistical aspects of the trial, 
with particular focus on the implications of the chosen rule for early stopping of unsuccessful 
groups. We have shown that the operating characteristics of the rule are appropriate and that 
interim analyses can be timed to detect failing groups at various stages. 
Given the pressures on funding and time, it is desirable to test many aspects of treatment at once 
and to allow for the swift removal of unsuccessful strategies: Bayesian monitoring methods allow for 
this. Despite the focus on HCV treatment, the statistical principles behind our novel design are not 
limited to this area and could be applied to other clinical trials in a wide variety of settings. 
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Tables and figures 
Table 1: Components of each shortening strategy and cost differences compared with standard 12-week treatment 
Shortening strategy Resource use of providing treatment Difference in cost compared to standard 12-
week treatment 
Mean weeks 
of DAA 
Number of PEG-
IFN injections 
Number of 
visits required 
Number of 
VL tests 
Standard 12-week treatment 12  0 3* 1* - 
PEG-IFN+DAA (4 weeks treatment, 
weekly PEG-IFN) 
4  4 6 1 -8x(weekly drug cost) + 4x(interferon cost) + 
3x(visit cost) 
Response guided therapy  
(4, 8, or 12 weeks treatment) 
9.6**  0 4 2 -3.4x(weekly drug cost) + 1x(visit cost) +1x(VL 
cost) 
Induction/maintenance (7 days/week 
for 2 weeks, then 5 days/week) 
9.14 0 4† 1 -3.86x(weekly drug cost) + 1x(visit cost) 
* assuming minimum visits at treatment initiation, end of treatment, end of treatment plus 12 weeks (where VL is done once to assess cure)  
** assuming 1:3:1 receiving 4:8:12 weeks treatment. One extra visit and VL at day 7 to assess initial VL response 
† assuming one extra visit at week 2 when move from induction to maintenance phase 
PEG-IFN: pegylated-inteferon; DAA: direct acting antiviral. 
 
Table 2: Priors to be used in final analysis 
 Primary analysis: 
uninformative 
Sensitivity analyses 
Sceptical Enthusiastic 
Control cure rate  Beta(4.75, 0.25) Beta(4.75, 0.25) Beta(4.75, 0.25) 
Regimen comparison  N(0, 10000) N(-0.05, 0.009) N(0, 0.009) 
Strategy comparison  N(0, 10000) N(-0.1, 0.0036) N(0, 0.0036) 
Ribavirin comparison N(0, 10000) N(0, 0.009) N(0.05, 0.009) 
The beta prior for the control cure rate has mean 0.95 and variance 0.008. 
The model will also be adjusted for genotype, which will have the prior N(0, 10000) in all analyses. 
N(m,v) is the normal prior with mean m and variance v. 
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Table 3: Number of failures needed to stop a drug strategy group for each number of analysed patients 
Analysed 
patients 
Minimum number of 
observed failures needed 
to stop group* 
Maximum probability of stopping 
group if true cure rate equals: 
Minimum probability of stopping group if true cure rate equals: 
90% 95% 90% 80% 70% 60% 
3-7 3 0.026 0.004 0.001 0.008 0.027 0.064 
8-13 4 0.034 0.003 0.005 0.056 0.194 0.406 
14-20 5 0.043 0.003 0.009 0.130 0.416 0.721 
21-26 6 0.040 0.002 0.014 0.231 0.637 0.904 
27-33 7 0.042 0.001 0.015 0.287 0.744 0.958 
34-39** 8 0.037 0.001 0.017 0.367 0.844 0.986 
40-41** 8 0.048 0.001 0.042 0.563 0.945 0.998 
42-48 9 0.046 0.001 0.021 0.469 0.920 0.997 
49-55 10 0.044 0.0004 0.022 0.528 0.952 0.999 
56-63 11 0.047 0.0003 0.021 0.580 0.971 1.000 
64-71 12 0.048 0.0002 0.023 0.648 0.985 1.000 
72-78 13 0.045 0.0001 0.025 0.705 0.993 1.000 
* >0.95 posterior probability of the true cure rate being <90% (Pr(true cure rate <0.9|x)>0.95, where x is the data currently observed, with the beta(4.5, 0.5) 
prior which has mean=0.9 and variance=0.015 
**These rows not pooled despite the same number of minimum failures to provide information about the fully recruited strata (n=39). 
Note: Groups will recruit 78 patients with 39 patients in each stratum. 
Maximum and minimum probabilities are for the range of analysed patients. 
 
24 
 
Table 4: Timing of interim analyses 
 First Second Third Fourth 
Months since recruitment started 7 10 13 18 
Total recruited 205 361 517 777 
Total at EOT+12 weeks 44 144 286 533 
At EOT+12 weeks in each:     
  PEG-IFN group 5 14 24 42 
  RGT group 3 11 21 39 
  Induction/maintenance group 2 8 17 35 
Average probability genuinely inferior group 
will be stopped*: 
    
  PEG-IFN groups 0.124 0.297 0.537 0.710 
  RGT groups 0.021 0.313 0.440 0.665 
  Induction/maintenance groups 0.070 0.150 0.431 0.593 
*Assuming true cure rate uniformly distributed over 60-90% 
EOT+12: 12 weeks after the end of treatment; PEG-IFN: pegylated-interferon; RGT: response guided 
therapy 
 
Table 5: Group-specific cure rates and power for 1092 patients with an overall 95% cure rate  
 Ribavirin group cure rate compared to 12 
week standard treatment cure rate 
 5% higher 2.5% higher Equal 
Group-specific cure rates:    
  Standard 12 week treatment groups 93.3% 95% 96.7% 
  Shortened treatment with ribavirin groups 98.3% 97.5% 96.7% 
  Shortened treatment without ribavirin groups 93.3% 92.5% 91.7% 
Power for a:    
  5% non-inferiority margin for regimen comparison 99% 98% 97% 
  10% non-inferiority margin for strategy comparison 100% 100% 96% 
  5% absolute difference for ribavirin comparison 98% 95% 91% 
Note: Group-specific cure rates are such that overall cure rate in 1092 patients is 95%, ribavirin 
effect between shortened treatment groups is 5% and there is no effect of regimen. The effect of 
ribavirin in shortened treatment compared to standard treatment is varied to reflect uncertainties in 
the cure rates and to vary the no effect of strategy between standard treatment and shortened 
treatment without ribavirin, shortened treatment with ribavirin and pooled shortened treatment 
groups. Power is calculated with one sided alpha=0.05 for non-inferiority margins and two-sided 
alpha=0.05 for superiority comparisons reflecting the design. 
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Figure Legends 
Figure 1: Trial Schema 
 
Note: SOF/VEL=sofosbuvir/velpatasvir, SOF/DCV=sofosbuvir/daclatasvir, RBV=ribavirin, VL=viral 
load, RGT=response guided therapy, PEGIFN=pegylated interferon. 
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Figure 2: Initial probability of stopping groups over an estimated recruitment schedule for various 
true cure rates 
 
Note: The average true cure rate is uniformly distributed over 60-90%. Probabilities are calculated 
assuming no previous interim analysis. The total number of patients recruited at each month, of a 
total target of 1092, is: 113 at 5 months, 153 at 6, 205 at 7, 257 at 8, 309 at 9, 361 at 10, 413 at 11, 
465 at 12, 517 at 13, 569 at 14, 621 at 15, 673 at 16, 725 at 17, 777 at 18, 829 at 19, 881 at 20, 933 
at 21, 985 at 22, 1037 at 23 and 1092 at 24. See Supplementary Figure 1, Additional File 1 for the 
cumulative probability of stopping a group. 
 
